DK2459230T3 - Oligonukleotider, der inhiberer cellulær migration - Google Patents
Oligonukleotider, der inhiberer cellulær migration Download PDFInfo
- Publication number
- DK2459230T3 DK2459230T3 DK10735303.9T DK10735303T DK2459230T3 DK 2459230 T3 DK2459230 T3 DK 2459230T3 DK 10735303 T DK10735303 T DK 10735303T DK 2459230 T3 DK2459230 T3 DK 2459230T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- tumor
- tsp1
- cells
- double
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (11)
1. Anvendelse af et dobbeltstrenget oligonukleotid, der er valgt blandt parret (SEQ ID NO: 1 og SEQ ID NO: 2), parret (SEQ ID NO: 21 og SEQ ID NO: 22), parret (SEQ ID NO: 3 og SEQ ID NO: 4) eller parret (SEQ ID NO: 23 og SEQ ID NO: 24), til fremstilling af et lægemiddel til forebyggelse eller behandling af primære tumorer eller invasive eller metastatiske tumorer.
2. Anvendelse af et produkt, der indeholder eller består af: - mindst et dobbeltstrenget oligonukleotid ifølge krav 1, - mindst et anti-angiogent middel og/eller et anti-tumoralt middel, til fremstilling af et kombinationsprodukt til samtidig eller separat anvendelse eller anvendelse spredt over tid til forebyggelse eller behandling af primære tumorer eller invasive eller metastatiske tumorer.
3. Dobbeltstrenget oligonukleotid til anvendelse ifølge krav 1 eller produkt til anvendelse ifølge krav 2, hvor lægemidlet er kombineret med anti-tumoral behandling, såsom stråleterapi eller kemoterapi.
4. Dobbeltstrenget oligonukleotid til anvendelse eller produkt til anvendelse ifølge krav 3, hvor den primære tumor eller invasive eller metastatiske tumor er en fast tumor eller en lymfoproliferativ tumor, hvor den faste tumor er en prostatatumor, en levertumor, hepatiske adenomaer, fokal nodulær hyper-plasi, en hjernetumor såsom gliom, en brysttumor, en nyretumor, en lungetumor såsom ikke-småcellet lungekarcinom, småcellet lungekarcinom, pleu-ropulmonalt biastom og karcinoid tumor, en knogletumor såsom osteom, osteochondrom, aneurysmal knoglecyste og fibrøs dysplasi, osteosarkom, chondrosarkom, Ewings sarkom, malignt fibrøst histiocytom, fibrosarkom, en mavecancer, en kolontumor, en tyndtarmstumor, en spiserørstumor, en bug-spytkirteltumor, et sarkom, en livmoderhalstumor, en galdeblæretumor, et melanom, og hvor lymfoproliferativ tumor er leukæmi, lymfom eller myeloma-tose.
5. Farmaceutisk sammensætning, omfattende som aktivt stof, mindst et dobbeltstrenget oligonukleotid, der er valgt blandt de følgende par bestående af (SEQ ID NO: 1 og SEQ ID NO: 2); (SEQ ID NO: 3 og SEQ ID NO: 4); (SEQ ID NO: 21 og SEQ ID NO: 22); (SEQ ID NO: 23 og SEQ ID NO: 24), sammen med et farmaceutisk acceptabelt hjælpestof.
6. Farmaceutisk sammensætning ifølge krav 5, hvor det aktive stof er formuleret til administration i en dosis i intervallet på fra 0,05 til 50 mg/kg, især 0,1 til 20 mg/kg.
7. Farmaceutisk sammensætning omfattende, som aktivt stof, et produkt, der indeholder eller består af: - mindst et dobbeltstrenget oligonukleotid ifølge krav 1, - mindst et anti-angiogent middel og/eller et anti-tumoralt middel, som et kombinationsprodukt til samtidig eller separat anvendelse eller anvendelse spredt over tid.
8. Farmaceutisk sammensætning ifølge krav 7, hvor det anti-angiogene middel er valgt fra gruppen, der omfatter Cilengitid, Vandetanib, Lenalidomid, Thalidomid, Arseniktrioxid, Bevacizumab, anti-VEGFR-1, anti-VEGFFt-2, anti-PDGFR, anti-FMS-FLT-3, anti-TK1.
9. Farmaceutisk sammensætning ifølge krav 8, hvor det anti-tumorale middel er valgt fra gruppen, der omfatter alkylerende midler såsom Bendamustin, Temozolomid, Mechlorethamin, Cyclophosphamid, Carmustin, Cisplatin, Busulfan, Thiotepa eller Decarbazin, anti-metabolitter såsom Pentostatin, Methotrexat, Pemetrexed, Floxuridin, Fluorouracil, Cytarain, Mercaptopurin eller Thiguanin, cytotoksiske antibiotika såsom Rubitecan, Mitomycin C, Daunorubicin, Doxorubicin, Bleomycin, Plicamycin, Mitoxantron HCI eller Oxaliplatin, plantederivater såsom Vinorelbin, BMS 184476, Vincristinsulfat, Vinblastin, Docetaxeltaxol.
10. Oligonukleotidsekvens, der er valgt blandt de følgende sekvenser: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24.
11. Dobbeltstrenget oligonukleotid, der er valgt blandt de følgende par, der består af (SEQ ID NO: 1 og SEQ ID NO: 2); (SEQ ID NO: 3 og SEQ ID NO: 4); (SEQ ID NO: 21 og SEQ ID NO: 22); (SEQ ID NO: 23 og SEQ ID NO: 24).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305723A EP2283870A1 (en) | 2009-07-31 | 2009-07-31 | Oligonucleotides inhibiting cellular migration |
| PCT/EP2010/061156 WO2011012716A1 (en) | 2009-07-31 | 2010-07-30 | Oligonucleotides inhibiting cellular migration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2459230T3 true DK2459230T3 (da) | 2014-12-08 |
Family
ID=41727858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10735303.9T DK2459230T3 (da) | 2009-07-31 | 2010-07-30 | Oligonukleotider, der inhiberer cellulær migration |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8765705B2 (da) |
| EP (2) | EP2283870A1 (da) |
| JP (1) | JP5779178B2 (da) |
| CA (1) | CA2769538C (da) |
| DK (1) | DK2459230T3 (da) |
| ES (1) | ES2525255T3 (da) |
| PL (1) | PL2459230T3 (da) |
| PT (1) | PT2459230E (da) |
| WO (1) | WO2011012716A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105377344B (zh) | 2013-03-13 | 2019-08-30 | 努瓦拉公司 | 液体输送系统和治疗方法 |
| EP3272880B1 (en) * | 2013-03-15 | 2020-11-25 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
| EP3156497A1 (en) * | 2015-10-16 | 2017-04-19 | Centre National de la Recherche Scientifique (C.N.R.S.) | Trpv2 as a biomarker and as a therapeutic target for melanoma |
| FR3058061A1 (fr) * | 2016-10-27 | 2018-05-04 | Selexel | Nouvelle utilisation d'oligonucleotides double brin |
| CA3041630A1 (fr) * | 2016-10-27 | 2018-05-03 | Selexel | Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006010492A1 (en) * | 2004-07-28 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with tryptase 1 (tps1) |
| US20100292316A1 (en) * | 2007-07-18 | 2010-11-18 | Research Development Foundation | Improved therapeutic methods and compositions comprising chroman ring compounds |
-
2009
- 2009-07-31 EP EP09305723A patent/EP2283870A1/en not_active Withdrawn
-
2010
- 2010-07-30 JP JP2012522187A patent/JP5779178B2/ja not_active Expired - Fee Related
- 2010-07-30 CA CA2769538A patent/CA2769538C/en not_active Expired - Fee Related
- 2010-07-30 ES ES10735303.9T patent/ES2525255T3/es active Active
- 2010-07-30 PL PL10735303T patent/PL2459230T3/pl unknown
- 2010-07-30 WO PCT/EP2010/061156 patent/WO2011012716A1/en active Application Filing
- 2010-07-30 EP EP10735303.9A patent/EP2459230B1/en active Active
- 2010-07-30 US US13/387,829 patent/US8765705B2/en active Active
- 2010-07-30 PT PT107353039T patent/PT2459230E/pt unknown
- 2010-07-30 DK DK10735303.9T patent/DK2459230T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013500709A (ja) | 2013-01-10 |
| US8765705B2 (en) | 2014-07-01 |
| US20120195890A1 (en) | 2012-08-02 |
| ES2525255T3 (es) | 2014-12-19 |
| PT2459230E (pt) | 2014-12-11 |
| PL2459230T3 (pl) | 2015-03-31 |
| JP5779178B2 (ja) | 2015-09-16 |
| EP2459230A1 (en) | 2012-06-06 |
| EP2283870A1 (en) | 2011-02-16 |
| WO2011012716A1 (en) | 2011-02-03 |
| CA2769538A1 (en) | 2011-02-03 |
| CA2769538C (en) | 2020-12-01 |
| EP2459230B1 (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gambari et al. | Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology | |
| Alečković et al. | Regulation of cancer metastasis by cell-free miRNAs | |
| Ryu et al. | Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration | |
| Ohyagi-Hara et al. | miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression | |
| Pramanik et al. | Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice | |
| Ugrinova et al. | Multifaceted nucleolin protein and its molecular partners in oncogenesis | |
| Xu et al. | MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17 | |
| Zhang et al. | miR-218 inhibited tumor angiogenesis by targeting ROBO1 in gastric cancer | |
| Wierinckx et al. | MicroRNAs in pituitary tumors | |
| Lee et al. | Cancer-associated fibroblasts activated by miR-196a promote the migration and invasion of lung cancer cells | |
| Ananta et al. | Tailored nanoparticle codelivery of antimiR-21 and antimiR-10b augments glioblastoma cell kill by temozolomide: toward a “personalized” anti-microRNA therapy | |
| Nairismägi et al. | The proto-oncogene TWIST1 is regulated by microRNAs | |
| Hao et al. | The synergistic regulation of VEGF-mediated angiogenesis through miR-190 and target genes | |
| DK2459230T3 (da) | Oligonukleotider, der inhiberer cellulær migration | |
| Lee et al. | MicroRNA-296-5p promotes invasiveness through downregulation of nerve growth factor receptor and caspase-8 | |
| US20100016406A1 (en) | Antisense RNA for Treating Cancer and Inhibition of Metastasis and Vectors for Antisense Sequestration | |
| Bhagirath et al. | MicroRNAs as regulators of prostate cancer metastasis | |
| Xie et al. | Circular RNA circ_0047744 suppresses the metastasis of pancreatic ductal adenocarcinoma by regulating the miR-21/SOCS5 axis | |
| US9512425B2 (en) | Inhibiting migration of cancer cells | |
| Kondetimmanahalli et al. | Noncoding RNAs: Novel targets in anticancer drug development | |
| WO2020025710A1 (en) | Micro rna for use in the prevention and/or treatment of invasive cancer | |
| Zhao et al. | Bone metastasis-related Micrornas: New targets for treatment? | |
| US20100113577A1 (en) | Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer | |
| KR101445921B1 (ko) | ｍｉＲ-185의 항암적 용도 | |
| US20210369758A1 (en) | DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNA |